Murine model of FLT3-ITD and IDH2 co-mutated AML showed that enasidenib treatment significantly reduced 2-HG levels and induced demethylation of hypermethylated CpG islands, but enasidenib alone was not enough to suppress the malignant clones. This evidence concerns the gene FLT3 and acute myeloid leukemia.